Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:29 July 2010
Reviewer: Silvia Melgar
Reviewer's report:
The paper by Kverka et al, describes the efficacy and safety of 6-TG in
comparison to AZA in an acute model of colitis.
The work is correctly performed with good number of mice per treatment group
as well as analysis performed. Although the authors show a safe and efficacious
treatment using 6-TG over AZA in this murine model, I have some concerns
regarding the study.
Major comments
Is AZA and/or 6TG well absorbed by the gut?
In order to induce remission by AZA, IBD patients are treated for much longer
period of time than the current study i.e.9 days, have the authors used a longer
AZA-treatment in a chronic model of colitis?
Is 6-TG safe and efficacious in a chronic model of colitis?
Is the infiltration/injury seen in AZA-treated DSS-colitic mice also found in healthy
mice? Or is the effect exagereated by inflammation? Similarly, the authors seem
to detect some infiltration in 6-TG treated mice, have they analysed healthy
treated mice? These experiments should be included as controls to the provided
data.
Have the authors analysed the expression of cytokines in the colon?
Minor comments
Liver fig from 6TG treated mice should be included in Fig 3
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interest
Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:29 July 2010
Reviewer: Silvia Melgar
Reviewer's report:
The paper by Kverka et al, describes the efficacy and safety of 6-TG in
comparison to AZA in an acute model of colitis.
The work is correctly performed with good number of mice per treatment group
as well as analysis performed. Although the authors show a safe and efficacious
treatment using 6-TG over AZA in this murine model, I have some concerns
regarding the study.
Major comments
Is AZA and/or 6TG well absorbed by the gut?
In order to induce remission by AZA, IBD patients are treated for much longer
period of time than the current study i.e.9 days, have the authors used a longer
AZA-treatment in a chronic model of colitis?
Is 6-TG safe and efficacious in a chronic model of colitis?
Is the infiltration/injury seen in AZA-treated DSS-colitic mice also found in healthy
mice? Or is the effect exagereated by inflammation? Similarly, the authors seem
to detect some infiltration in 6-TG treated mice, have they analysed healthy
treated mice? These experiments should be included as controls to the provided
data.
Have the authors analysed the expression of cytokines in the colon?
Minor comments
Liver fig from 6TG treated mice should be included in Fig 3
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interest
Please review this paper.
user
Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:29 July 2010
Reviewer: Silvia Melgar
Reviewer's report:
The paper by Kverka et al, describes the efficacy and safety of 6-TG in
comparison to AZA in an acute model of colitis.
The work is correctly performed with good number of mice per treatment group
as well as analysis performed. Although the authors show a safe and efficacious
treatment using 6-TG over AZA in this murine model, I have some concerns
regarding the study.
Major comments
Is AZA and/or 6TG well absorbed by the gut?
In order to induce remission by AZA, IBD patients are treated for much longer
period of time than the current study i.e.9 days, have the authors used a longer
AZA-treatment in a chronic model of colitis?
Is 6-TG safe and efficacious in a chronic model of colitis?
Is the infiltration/injury seen in AZA-treated DSS-colitic mice also found in healthy
mice? Or is the effect exagereated by inflammation? Similarly, the authors seem
to detect some infiltration in 6-TG treated mice, have they analysed healthy
treated mice? These experiments should be included as controls to the provided
data.
Have the authors analysed the expression of cytokines in the colon?
Minor comments
Liver fig from 6TG treated mice should be included in Fig 3
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interest
assistant